Published in Gastroenterology on November 01, 1992
Expression of the human cell surface glycoconjugates Lewis x and Lewis y by Helicobacter pylori isolates is related to cagA status. Infect Immun (1996) 1.88
H pylori colocalises with MUC5AC in the human stomach. Gut (2000) 1.78
Host Lewis phenotype-dependent Helicobacter pylori Lewis antigen expression in rhesus monkeys. FASEB J (2006) 0.95
Detection of sulfated glycoproteins in intestinal metaplasia: a comparison of traditional mucin staining with immunohistochemistry for the sulfo-Lewis(a) carbohydrate epitope. J Clin Pathol (2003) 0.79
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med (1993) 2.74
Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology (1987) 2.54
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology (1999) 2.46
Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl (1999) 1.97
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology (2000) 1.84
Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest (1996) 1.81
Is colorectal cancer screening necessary in the preoperative assessment of inguinal herniorrhaphy? A case-control study. Am J Gastroenterol (2001) 1.71
Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol (2000) 1.63
Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc (2001) 1.62
Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract (2005) 1.56
Testing negative for Helicobacter pylori after methylene blue spraying of gastric mucosa. Gastrointest Endosc (1994) 1.45
Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest (1988) 1.41
Endoscopic appearances of colonic lymphoid nodules: new faces of an old histopathological entity. Am J Gastroenterol (1995) 1.40
Upright versus supine reflux in gastroesophageal reflux disease. J Gastroenterol Hepatol (2001) 1.40
Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol (2001) 1.30
Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. Hepatology (1992) 1.22
Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther (2004) 1.22
Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol (1998) 1.18
Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol (2001) 1.17
Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: a porcine model. Gastrointest Endosc (2000) 1.16
Acid and bile reflux in Barrett's esophagus: a tale of two evils. Gastroenterology (2001) 1.16
Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: association of lipid peroxidation with liver fibrogenesis. Hepatology (1992) 1.14
Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus (2007) 1.13
Dietary habits and right-sided colonic diverticulosis. Dis Colon Rectum (2000) 1.12
Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa. Gastroenterology (1986) 1.11
Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol (1992) 1.07
The surgical management of severe gastroparesis in heart/lung transplant recipients. Chest (2000) 1.04
Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. Am J Physiol (1998) 1.02
E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. Am J Gastroenterol (1995) 1.02
Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus (2003) 1.02
Endoscopic evaluation of esophago-gastro-jejunostomy in rat model of Barrett's esophagus. Dis Esophagus (2009) 1.00
Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol (2000) 1.00
Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis (1998) 0.98
Acid modulation of HT29 cell growth and differentiation. An in vitro model for Barrett's esophagus. J Cell Sci (1997) 0.98
Review article: approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? Aliment Pharmacol Ther (2004) 0.98
Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology (1997) 0.97
Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther (2001) 0.93
A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol (2000) 0.92
Multifocal heterogeneity in villin and Ep-CAM expression in Barrett's esophagus. Int J Cancer (1996) 0.92
S, m, l, xl. Gut (2003) 0.90
Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig Liver Dis (2005) 0.90
Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2004) 0.89
Gastroesophageal reflux disease in patients with spinal cord injury. J Spinal Cord Med (2000) 0.88
Secretin-stimulated amylase release into blood is impaired in type 1 diabetes mellitus. Horm Metab Res (2005) 0.88
Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus. Dis Esophagus (2008) 0.86
Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy. Dis Esophagus (2012) 0.85
Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients who take anticoagulants. Am J Gastroenterol (2000) 0.84
Mast cell and substance P-positive nerve involvement in a patient with both irritable bowel syndrome and interstitial cystitis. Urology (1996) 0.84
Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon. Cancer Res (1993) 0.84
Glycogenic acanthosis of the esophagus and gastroesophageal reflux. J Clin Gastroenterol (1993) 0.84
Barrett's-related esophageal adenocarcinoma: is chemoprevention a potential option? Am J Gastroenterol (2001) 0.83
Effect of purified Clostridium difficile toxins on intestinal smooth muscle. I. Toxin A. Am J Physiol (1989) 0.83
A modification of the quininium resin test for assessing gastric acidity. Aliment Pharmacol Ther (2002) 0.81
Novel adaptation of brush cytology technique for short-term primary culture of squamous and Barrett's esophageal cells. Gastrointest Endosc (2001) 0.80
Failure of initial 24-hour esophageal pH monitoring to predict refractoriness and intractability in reflux esophagitis. Am J Gastroenterol (1991) 0.79
Reasons for current practices in managing Barrett's esophagus. Dis Esophagus (2002) 0.79
Serum 13C-bicarbonate in the assessment of gastric Helicobacter pylori urease activity. Am J Gastroenterol (1993) 0.78
Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther (2007) 0.78
Endoscopic ablation therapy of Barrett's esophagus. Minerva Gastroenterol Dietol (2010) 0.78
A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. Dig Liver Dis (2005) 0.76
Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment. Gastroenterology (1997) 0.76
Esophageal manifestations of rheumatic disorders. Semin Arthritis Rheum (1997) 0.76
"Spontaneous sump syndrome": Successful treatment by duodenoscopic sphincterotomy. Am J Gastroenterol (1990) 0.75
Primary esophageal motility disorders: incisive decisions. West J Med (1997) 0.75
Treatment of gastroesophageal reflux disease--1998. West J Med (1998) 0.75
"Quality time" for patients with Barrett's esophagus. Endoscopy (2010) 0.75
Evaluation and management of patients with symptoms after anti-reflux surgery. Dis Esophagus (2013) 0.75
Palliative care in inflammatory bowel disease: an evidence-based approach. Inflamm Bowel Dis (2000) 0.75
Nodular duodenitis and single duodenal nodules. Am Surg (1990) 0.75
Trypsin radioimmunoassay. J Pediatr Gastroenterol Nutr (1989) 0.75
Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2000) 0.75
Early dysphagia after placement of a self-expanding esophageal stent: severe esophagitis mimicking luminal occlusion. Am J Gastroenterol (1995) 0.75
Esophageal submucosal gland duct adenoma. Am J Surg Pathol (1995) 0.75
Clostridium difficile toxin A stimulates enzyme secretion from isolated rat pancreatic acini. Mater Med Pol (1994) 0.75
Esophageal wall thickening: a CT finding in diffuse esophageal spasm. J Comput Assist Tomogr (1997) 0.75
Oesophageal mucosal diseases in the elderly. Drugs Aging (1998) 0.75
Antibiotic-associated colitis. Compr Ther (1985) 0.75
Whole greater than the parts: integrated esophageal centers (IEC) and advanced training in esophageal diseases. Dis Esophagus (2017) 0.75